Form 4: Kiniksa Pharmaceuticals Executive Equity Transactions

Eben Tessari, Chief Strategy Officer at Kiniksa Pharmaceuticals, reports on recent transactions involving Class A Ordinary Shares, including acquisitions and grants of equity awards.

Summary

• Eben Tessari, Chief Strategy Officer of Kiniksa Pharmaceuticals International, plc, has reported several transactions related to the company's Class A Ordinary Shares.
• These transactions include the acquisition of shares under the Issuer's 2018 Employee Share Purchase Plan, as well as the grant and vesting of Restricted Share Units (RSUs) and Performance Share Units (PSUs).
• The earliest reported transaction date is January 15, 2026, with subsequent transactions on April 1, 2026.
• Tessari's beneficial ownership of Class A Ordinary Shares has been updated following these events.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider equity transactions and awards, which are standard for executive compensation and do not inherently signal positive or negative performance.

Positives

• Acquisition of 365 Class A Ordinary Shares on January 15, 2026, at a price of $24.16 per share, indicating employee participation in share ownership.
• Acquisition of 5,975 Class A Ordinary Shares on April 1, 2026, with a transaction code 'A', suggesting an award or grant.
• Grant of 33,200 stock options with an exercise price of $48.13, vesting commencing April 1, 2026.
• Grant of 8,300 Restricted Share Units (RSUs) vesting over a four-year period starting April 1, 2026.
• Grant of 16,600 Performance Share Units (PSUs) with potential to vest into up to 200% of Class A Ordinary Shares by January 30, 2028.
• Vesting of 1,773 RSUs on April 1, 2026, related to a grant on April 1, 2023.
• Vesting of 1,745 RSUs on April 1, 2026, related to a grant on April 1, 2024.
• Vesting of 2,457 RSUs on April 1, 2026, related to a grant on April 1, 2025.

Negatives

• The filing details the disposal of 1,756 Class A Ordinary Shares on April 1, 2026, at a price of $48.13, which could represent a sale or tax withholding.

Risks

• Performance Share Units (PSUs) are contingent on the achievement of pre-established performance criteria, meaning the actual number of shares received may vary or be forfeited.
• Vesting of stock options, RSUs, and PSUs is subject to continued employment and performance conditions, which could lead to forfeiture if not met.

Future Outlook

The filing does not contain forward-looking statements or guidance. It primarily reports on past transactions and grants of equity awards with specified vesting schedules and performance conditions.

Management Comments

• The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
• Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
• Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock. The details provided by Eben Tessari are typical for a Chief Strategy Officer, reflecting participation in employee stock purchase plans and receipt of equity-based compensation designed to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The transactions reflect executive compensation and potential future dilution if equity awards vest and are exercised. The disposal of shares could indicate a liquidity event for the executive.
• Employees: The Employee Share Purchase Plan participation and RSU/PSU grants demonstrate a commitment to employee incentives and retention.
• Management: The transactions directly impact the beneficial ownership of the Chief Strategy Officer, aligning their interests with the company's performance through equity awards.

Next Steps

• Vesting of stock options commencing April 1, 2026.
• Vesting of RSUs over a four-year period starting April 1, 2026.
• Achievement of performance criteria for PSUs to determine vesting, with a deadline of January 30, 2028.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Form 4, SEC Filing, Insider Trading, Equity Awards, Stock Options, Restricted Stock Units, Performance Share Units, Class A Ordinary Shares, Eben Tessari, Chief Strategy Officer